Does Big Science have a bullying problem? Why did the FDA change its tune on China? And what’s cooler than $100 billion?
We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. We discuss the scandalous end of Eric Lander’s tenure as presidential science adviser with STAT Washington correspondent Lev Facher and science writer Megan Molteni. Then we dive into the FDA’s about-face on cancer drugs developed in China and what it means for the cost of medicine in the U.S. We also explain how Pfizer’s record-setting year somehow disappointed Wall Street and explore whether it’s a good idea to end mask mandates.
Patients want change; providers agree — we need to disrupt the status quo
Inequities within the U.S. healthcare system are worsening for medically disenfranchised patients. Genentech believes sustainable solutions require a deeper understanding of their experiences. We surveyed underserved patients and their healthcare providers to learn more about their perceptions of and experiences with the healthcare system. See what they had to say here.
No comments